Sign up to get notified if we do in the future.
We guarantee the lowest price on all of our prescription products. If you find your medications cheaper at any other recognized licensed mail order pharmacy, we will not only match their price, we will beat it by 25% of the difference. It is our 125% price match guarantee!
Example: If you find a product on Canada Drugs Direct for $50.00 and find the same product for $40.00 at another mail order pharmacy, we will provide you with a $12.50 discount, bringing your total to $37.50.
To get the discount please make sure to mention the price match to the customer service team when they call to collect payment for your order. Or call toll free at 1-888-904-8467 to place the order through the phone.
Terms & Conditions of Program
A generic drug is a copy of the brand-name drug with the same dosage, safety, strength, quality, consumption method, performance, and intended use. Before generics become available on the market, the generic company must prove it has the same active ingredients as the brand-name drug and works in the same way and in the same amount of time in the body.
The only differences between generics and their brand-name counterparts is that generics are less expensive and may look slightly different (eg. different shape or color), as trademarks laws prevent a generic from looking exactly like the brand-name drug.
Generics are less expensive because generic manufacturers don't have to invest large sums of money to develop a drug. When the brand-name patent expires, generic companies can manufacture a copy of the brand-name and sell it at a substantial discount.
Welireg is a prescription medication that treats von Hippel-Lindau (VHL) disease in people with hemangioblastomas, renal cell carcinoma (RCC), or pancreatic neuroendocrine tumors (pNET).
Welireg works by inhibiting the activity of hypoxia-inducible factor-2 alpha (HIF-2a), a protein that plays a key role in promoting tumor growth. By blocking HIF-2a, Belzutifan helps to suppress the formation and progression of renal cell carcinoma.
Fact Table | |
Formula |
C17H12F3NO4S |
License |
US DailyMed |
Bioavailability |
No Data Available |
Legal status |
Rx-Only |
Chemical Name |
Belzutifan |
Elimination half-life |
14 hours |
Dosage (Strength) |
- |
Pregnancy |
Consult Doctor |
Brands |
Welireg |
Protein binding |
45% |
PubChem CID |
117947097 |
MedlinePlus |
a621047 |
ChEBI |
No Data Available |
ATC code |
L01XX74 |
DrugBank |
DB15463 |
KEGG |
D11954 |
Routes of administration |
By mouth |
The usual dosage is 120 mg by mouth once daily, with or without food. Welireg is available as 40 mg tablets.
The active ingredient in Welireg is belzutifan.
Common drug-drug interactions may include:
Your healthcare provider should monitor for symptoms of anemia during treatment. Monitoring may include watching for symptoms and checking blood labs. If anemia occurs, Welireg may need to be discontinued.
Oxygen saturation should be monitored before and during treatment with Welireg. If low oxygen (hypoxia) occurs, Welireg should be temporarily stopped. For life-threatening hypoxia, Welireg should be discontinued.
There are many potential drug-drug interactions with this medication. Tell your doctor about everything you are taking before starting this drug.
The most common adverse effects are:
Welireg [package insert]. Whitehouse Station, NJ: Merck; 2021.